ImmunityBio, Inc. IBRX Operating Income
Operating Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s operating income?
- ImmunityBio, Inc. (IBRX) reported operating income of -$69.79M in Q1 2026.
- How has ImmunityBio, Inc.'s operating income changed year-over-year?
- ImmunityBio, Inc.'s operating income decreased by 8.3% year-over-year, from -$64.43M to -$69.79M.
- What is the long-term trend for ImmunityBio, Inc.'s operating income?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s operating income has grown at a -6.2% compound annual growth rate (CAGR), from -$330.28M to -$256.03M.
- What does operating income mean?
- The profit a company makes from its core business operations before interest and taxes.
- How do you interpret operating income?
- A positive and growing operating income indicates a self-sustaining business model, while negative values indicate reliance on external financing.
- How does operating income compare across companies?
- Often negative for early-stage biotech companies that prioritize R&D over immediate profitability.